医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces License of PeptiDream’s Peptide Discovery Platform System (PDPS) Technology to Novartis

2015年04月02日 AM08:00
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”)(TOKYO:4587) announced today that Swiss-based Novartis has exercised its option under their 2012 Strategic Alliance Agreement to obtain a nonexclusive license to PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology. Under the terms of the Technology License Agreement, PeptiDream will receive multi-stage upfront technology access payments, and will be eligible to receive development milestones and royalties on future sales of products that arise from use of the PDPS technology.

Comments from Kiichi Kubota, CEO of PeptiDream Inc.

We are delighted with Novartis’s decision to internalize the PDPS technology under our 2012 Strategic Alliance Agreement, and this exercise further validates our PDPS technology as one of the best hit-finding/discovery platforms. The license agreement will significantly contribute to PeptiDream’s revenue both in the short term and has the potential to generate significant revenues long into the future.

About PeptiDream Inc.

PeptiDream Inc. is a public (Tokyo Stock Exchange Mothers 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics.

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc